Photo

613-801-0510

...

Ottawa

English, French

Suzanne Hof, Ph.D.

Senior Patent Agent

Suzanne Hof’s responsibilities at MBM include the drafting and prosecuting of biochemical, pharmaceutical, chemical as well as "cleantech and green technology" patents. Suzanne also has expertise in the Patented Medicines (Notice of Compliance) Regulations, particularly on issues relating to timing, information and drug submission requirements for listing a patent on the Patent Register.

Upon completion of her doctoral studies at the University of Alberta, Suzanne spent two years as a Visiting Fellow at the Steacie Institute for Molecular Sciences at the National Research Council of Canada before beginning her patent law career.

Suzanne has co-authored scientific publications related to carbohydrate synthesis and both solid and solution-phase organic synthesis, and has presented her work at a number of international conferences and symposia. She has a broad research background which includes practical experience in oligosaccharide synthesis (both chemical and enzymatic), synthetic organic chemistry (including solid-phase synthetic methods), as well as various biochemical and analytical methods. Suzanne`s doctoral thesis related to the synthesis of GM1 analogues and investigated the binding of these analogues to cholera and heat-labile enterotoxins.

Suzanne is a Registered Canadian Patent Agent.

Education

  • B.Sc., (Spec.), Chemistry, University of Alberta

  • Ph.D., Organic Chemistry, University of Alberta

Technology Area

cb photo 111 561d6b13433c5JONATHAN ROCH

Partner

Jonathan assists clients with their intellectual property rights including patents, trademarks, copyrights, industrial designs and trade secretsMBM read_more_btn

MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

Clarifications to the Data Protection Guidance Document

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for...Read More